Press release
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
- GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed - - GB001 intellectual property estate strengthened with issuance
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n- GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed -\n\n\n- GB001 intellectual property estate strengthened with issuance of new patent by USPTO covering lysine salt drug substance forms -\n\n\n- GB004 completed successful Phase 1b in ulcerative colitis; Phase 2 trial planned to commence in 2020 -\n\n\n- GB004 license agreement with Aerpio amended to provide financial, milestone and royalty benefit to Gossamer -\n\n\n- Chief Medical Officer Jakob Dupont, M.D. to depart Gossamer; will continue to provide medical support to Gossamer’s GB1275 oncology program as a consultant -\n\n\n- Cash, cash equivalents and marketable securities totaled $346 million as of March 31, 2020 -\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the first quarter 2020 and provided a corporate update.\n\n\n“We are very pleased today to share initial results of the Gossamer team’s great execution and hard work, including that we have successfully completed the interim analysis of the LEDA study of GB001,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “We have begun initial Phase 3 planning and supportive activities, while awaiting final data from the study which will inform our decision to proceed to Phase 3.”\n\n\n“We are also excited to share topline results from our four-week Phase 1b study of GB004 in patients with active mild-to-moderate ulcerative colitis,” said Dr. Gujrathi. “The safety and tolerability data, in addition to the promising efficacy data observed in the study, give us confidence as we move into Phase 2.”\n\n\n“The trends observed in the clinical endpoints from a 28-day study with a limited number of patients, especially those endpoints that reflect GB004’s novel mechanism of action, such as histologic remission and mucosal healing, are very exciting,” said William Sandborn, M.D., Chief of the Division of Gastroenterology of University of California San Diego. “An oral, gut-targeted therapy with a non-immunosuppressive mechanism of action and a robust effect on mucosal healing would be a very meaningful addition to the ...